An Open-Label Trial Investigating the Pharmacokinetics and the Tolerability of NN9535 in Subjects With Normal Renal Function and Various Degrees of Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 27 Mar 2017 Results published in the Clinical Pharmacokinetics.
- 16 Sep 2014 Primary endpoint has been met (Area under the drug concentration-time curve of NN9535) according to results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 16 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History